DaveyB.DanielMD

Oncology • Chattanooga, TN

Physician

Join to view full profile

Dr. Daniel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Daniel's full profile

Already have an account?

Office
605 Glenwood Dr
Suite 200
Chattanooga, TN 37404
Phone+1 423-698-1844

Fax+1 423-624-2226
Is this information wrong?

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005
Duke University HospitalResidency, Internal Medicine, 1999 - 2002
Johns Hopkins University School of MedicineClass of 1999

Certifications & Licensure

GA State Medical License 2005 - 2025
TN State Medical License 2005 - 2025
NC State Medical License 1999 - 2006
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012

Clinical Trials

Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer Start of enrollment: 2009 Feb 01
Unknown status
Phase 3
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer Start of enrollment: 2015 Jul 01
Terminated
Phase 2
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11
Completed
Phase 2
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC Start of enrollment: 2021 Nov 03
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC.
Johan F Vansteenkiste, Jarushka Naidoo, Corinne Faivre-Finn, Mustafa Özgüroğlu, Augusto Villegas, Davey Daniel, Shuji Murakami, Rina Hui, Ki Hyeong Lee, Byoung Chul Ch...> ;JTO Clinical and Research Reports. 2024 Mar 1
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Thomas Stricker, Neha Jain, Esprit Ma, Elaine Yu, Rongrong Wang, Robert Schuldt, Richard Price, Tania Szado, Jesse Sussell, Sarika Ogale, Victor Lin, Edward Arrowsmith...> ;The Oncologist. 2024 Feb 28
Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in...
Jain, N., Fisher, A., Sheinson, D., Lofgren, K., Ma, E., Yu, E., Comment, L., Sincan, M., Martin, R., Zuniga, R., Vidal, G., Miksad, R., Daniel, D.> ;JCO Oncology Practice. 2024 Mar 1
4 citations
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
Tina Cascone, Gozde Kar, Jonathan D Spicer, Rosario García-Campelo, Walter Weder, Davey B Daniel, David R Spigel, Maen Hussein, Julien Mazieres, Julio Oliveira, Edwin ...> ;Cancer Discovery. 2023 Nov 1
12 citations
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
Lee S Schwartzberg, Gerald Li, Khaled Tolba, Ariel B Bourla, Katja Schulze, Rujuta Gadgil, Alexander Fine, Katherine T Lofgren, Ryon P Graf, Geoffrey R Oxnard, Davey D...> ;JTO Clinical and Research Reports. 2022 Sep 1
5 citations
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera, Davey B. Daniel, N. W. Peacock, L Finney, Susan J. Hoekstra, Mythili Shastry, John ...> ;Clinical Breast Cancer. 2021 Oct 28
15 citations
Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
Ray D. Page, Leylah Drusbosky, Hiba I. Dada, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers, Karen L. Reckamp, Miguel A. Villalona-Calero, Daniel Dix, Justin ...> ;Clinical Lung Cancer. 2021 Oct 10
19 citations
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Mark A. Socinski, Mustafa Ozguroglu, A. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Jhanelle E. Gray, Keunchil Park, M. Vincent, Helen Mann, Mi...> ;Clinical Lung Cancer. 2021 Jun 12
39 citations
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, pl...
Davey B. Daniel, Vladimer Kuchava, Igor Bondarenko, Oleksandr Ivashchuk, Sreekanth Reddy, Jana Jaal, Iveta Kudaba, Lowell L. Hart, Amiran Matitashvili, Yili Pritchett,...> ;International Journal of Cancer. 2021 May 15
31 citations
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results f...
Jared Weiss, Jerome H. Goldschmidt, Z. Andric, Konstantin H. Dragnev, Chad Gwaltney, Konstantina Skaltsa, Yili Pritchett, Joyce M Antal, Shannon R. Morris, Davey B. Da...> ;Clinical Lung Cancer. 2021 Mar 26
2 citations
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
Marina Chiara Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Ozguroglu, Davey B. Daniel, David Vicente, Shuji Murakami, ...> ;Future Oncology. 2021 Feb 15
6 citations
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non–Small-cell Lung Cancer (...
David R. Spigel, Robert M. Jotte, Santiago Ponce Aix, Laurent Gressot, Daniel Morgensztern, Michael McCleod, Mark A. Socinski, Davey B. Daniel, O. Juan-Vidal, Kathryn ...> ;Clinical Lung Cancer. 2021 Jan 1
23 citations
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
Corinne Faivre-Finn, David R. Spigel, Suresh Senan, Corey J. Langer, Bradford A. Perez, Mustafa Ozguroglu, Davey B. Daniel, A. Villegas, David Vicente, Rina Hui, Shuji...> ;Lung Cancer. 2021 Jan 1
91 citations
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
David M. Waterhouse, Edward B. Garon, Jason C. Chandler, Michael McCleod, Maen A. Hussein, Robert M. Jotte, Leora Horn, Davey B. Daniel, George P. Keogh, Ben C. Creela...> ;Journal of Clinical Oncology. 2020 Sep 10
22 citations
Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma.
Sara Bedrose, Kevin C. Miller, Mohamed S Ali, Sameh Nassar, Naveen Garg, Marilyne Daher, Keith D. Eaton, Jeffrey Yorio, Davey B Daniel, Matthew Campbell, Keith C. Bibl...> ;Journal for Immunotherapy of Cancer. 2020 Jul 1
276 citations
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
Jhanelle E. Gray, A. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Byoung Chul Cho, David Plan...> ;Journal of Thoracic Oncology. 2020 Feb 1
90 citations
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 st...
Rina Hui, Mustafa Ozguroglu, A. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Ch...> ;The Lancet. Oncology. 2019 Oct 7
122 citations
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including...
David R. Spigel, Michael McCleod, Robert M. Jotte, Lawrence H. Einhorn, Leora Horn, David M. Waterhouse, Ben C. Creelan, Sunil Babu, Natasha B. Leighl, Jason C. Chandl...> ;Journal of Thoracic Oncology. 2019 Sep 1
11 citations
Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B‐Cell Lymphoma Who Are Poor Candidates for R‐CHOP Chemotherapy
Ian W. Flinn, Jack Erter, Davey B. Daniel, Joseph R. Mace, Jesus G. Berdeja> ;The Oncologist. 2019 Aug 1
901 citations
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-...
Howard Jack West, Michael McCleod, Maen A. Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans-Georg Kopp, Davey B. Daniel, Steven L. McCune, Tarek...> ;The Lancet. Oncology. 2019 Jul 1
329 citations
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.
Natasha B. Leighl, Ray D. Page, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers, Karen L. Reckamp, Miguel A. Villalona-Calero, Daniel Dix, Justin I. Odegaard, ...> ;Clinical Cancer Research. 2019 Apr 15
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
Antonia, S. J.,Villegas, A.,Daniel, D.,Vicente, D.,Murakami, S.,Hui, R.,Kurata, T.,Chiappori, A.,Lee, K. H.,de Wit, M.,Cho, B. C.,Bourhaba, M.,Quantin, X.,Tokito, T.,M...> ;N. Engl. J. Med.. 2018 Oct 04
11 citations
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo-controlled phase 2 trial with...
David R. Spigel, Howard A. Burris, F. Anthony Greco, Kent C. Shih, Victor G. Gian, Andrew Lipman, Davey B. Daniel, David M. Waterhouse, L Finney, John V. Heymach, John...> ;Cancer. 2018 Jun 1
3 citations
Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
David R. Spigel, John D. Hainsworth, Dianna Shipley, Tarek Mekhail, John D. Zubkus, David M. Waterhouse, Davey B. Daniel, Howard A. Burris, F. Anthony Greco> ;Lung Cancer. 2018 Mar 1
657 citations
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Scott J Antonia, Augusto Villegas, Davey Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki H Lee, Maike de Wit, Byoung C Cho, Marya...> ;The New England Journal of Medicine. 2017 Nov 16
Join now to see all

Journal Articles

Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC
David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine

Press Mentions

Cancer Biomarker Testing: Teaming with Physicians to Ensure Access EverywhereFebruary 7th, 2023
OneOncology Adopts Slack as a Digital Headquarters for Physician CommunicationsOctober 24th, 2022
All 14 OneOncology Partner Practices Apply to Participate in EOMOctober 3rd, 2022
Join now to see all